Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
Cancer Immunology, Immunotherapy : CII|February 5, 2005
New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancerPierosandro Tagliaferri, Michele Caraglia, Alfredo Budillon, et al.
International Journal of Molecular Sciences|December 17, 2024
Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck CancersEmeshaw Damtew Zebene, Rita Lombardi, Biagio Pucci, et al.
Onkologie|June 7, 2007
Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapyGuglielmo Nasti, Gaetano Facchini, Michele Caraglia, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2012
A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcomeAnna Guerra, Laura Fugazzola, Vincenzo Marotta, et al.
Cancers|March 28, 2025
Serum-Based Proteomic Approach to Identify Clinical Biomarkers of Radiation ExposureEmeshaw Damtew Zebene, Biagio Pucci, Rita Lombardi, et al.
Scientific Reports|November 8, 2019
Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancerCarmine Nunziata, Andrea Polo, Angela Sorice, et al.
Scientific Reports|August 23, 2019
Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activityMichele Minopoli, Andrea Polo, Concetta Ragone, et al.
Molecules (Basel, Switzerland)|October 25, 2016
Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic ProfilesAngela Sorice, Francesco Siano, Francesca Capone, et al.
Oncotarget|January 27, 2018
HDAC inhibition potentiates immunotherapy in triple negative breast cancerManuela Terranova-Barberio, Scott Thomas, Niwa Ali, et al.
Oncotarget|August 28, 2015
Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acidValentina Bizzarro, Raffaella Belvedere, Maria Rita Milone, et al.
Pageof 16